-
Cytokinesis review(Post)
By John Bannon PhD Early Cytokinesis Early cytokinesis; from anaphase to midbody formation cytokinesis is the physical s
Citrullination, NETs and Rheumatoid Arthritis(Page) Enfortumab Vedotin: Unveiling Its Role in Cancer Treatment and the Rise of Biosimilars(Post)Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r
Interferons(Post)Interferons (IFNs) are a group of signalling proteins that are produced and released from cells in response to viral infection and other stimuli such as normal and tumour cell survival and
Fezakinumab: Exploring Its Mechanism and Clinical Potential(Post)Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses
Flow Cytometry Protocol | 10 Hints & Tips(Post)Lab Methods · Flow CytometryFlow Cytometry Protocol: Two Worked Protocols, Controls and 10 Practical TipsFlow cytometry measures individual cells in a fluid stream at hundreds per second, reporting si
B7-H3: A Promising New Target in Tumor Immunotherapy(Post)B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint molecules that has emerged as a compelling target in tumor immunotherapy. Initially recognized for its role i
Tiragolumab: Unlocking New Horizons in Cancer Immunotherapy(Post)Quick Facts About TiragolumabWhat is Tiragolumab?Tiragolumab is an anti-TIGIT monoclonal antibody developed to enhance immune responses against cancer cells. It is currently under invest
CD Markers Expression on B Cells(Post)Immunology · ImmunophenotypingCD Markers on B Cells: Development, Subsets and ImmunophenotypingB cells change their surface marker profile at every stage from bone marrow progenitor to antibody-secret
The Rat Effectively Models Signature Cytokines of T Helper Cells(Post)Understanding the immune system's intricacies requires models that accurately reflect its complexity. The rat, as a model organism, plays a crucial role in immunological research, particularly in
The Interferonopathies and the Self-DNA Problem(Page) COVID-19 Biomarkers(Post)SARS-CoV-2 Background COVID-19 is characterised by a series of biological markers. In some instances, these biomarkers can be used as potenti
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
Physiological and Pathological functions of IL-36(Post)By Charlotte O'Donnell PhD Similar to IL-33, IL-36R ligands are involved in maintaining intestinal homeostasis. Analogous to IL-33, d is locali
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
Unlocking the Next Wave of Cancer Treatment: The Promise and Progress of CAR-T Cell Therapy(Post)Imagine a living drug, engineered from a patient's own immune system, that can hunt down and destroy cancer cells with remarkable precision. This isn't science fiction; it's the reality of Chimeric An
Antigen Presenting Cells (APCs) and cancer immunotherapy(Post)Explore antigen presentation's crucial role in adaptive immunity and its impact on cancer immunotherapy, highlighting the diversity and function of MHC class I molecules. Key Takeaway
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research(Post)What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research(Post)What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
LILT: A Novel Immune Checkpoint for Cancer Therapy(Post)Recent advances in immunotherapy have highlighted the importance of targeting immune checkpoints to enhance the immune system’s ability to combat cancer. A new potential target in this gr